

Noël Zahr

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6155983/publications.pdf>

Version: 2024-02-01

29
papers

853
citations

623734

14
h-index

526287

27
g-index

29
all docs

29
docs citations

29
times ranked

1180
citing authors

#	ARTICLE	IF	CITATIONS
1	Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept. , 2022, 10, e004699.		29
2	Ciprofloxacin population pharmacokinetics during long-term treatment of osteoarticular infections. Journal of Antimicrobial Chemotherapy, 2021, 76, 2906-2913.	3.0	5
3	Mycophenolic acid area under the curve in patients with inflammatory myopathies. Rheumatology, 2021, 60, 3026-3028.	1.9	1
4	Evaluation of Hydroxychloroquine Blood Concentrations and Effects in Childhood-Onset Systemic Lupus Erythematosus. Pharmaceuticals, 2021, 14, 273.	3.8	12
5	An HPLC assay for the therapeutic drug monitoring of cefiderocol in critically ill patients. Journal of Antimicrobial Chemotherapy, 2021, 76, 1643-1646.	3.0	4
6	Development and clinical validation of a simple and fast UPLC-ESI-MS/MS method for simultaneous quantification of nine kinase inhibitors and two antiandrogen drugs in human plasma: Interest for their therapeutic drug monitoring. Journal of Pharmaceutical and Biomedical Analysis, 2021, 197, 113968.	2.8	15
7	Efficacy and safety of mexiletine in non-dystrophic myotonias: A randomised, double-blind, placebo-controlled, cross-over study. Neuromuscular Disorders, 2021, 31, 1124-1135.	0.6	14
8	Simple and accurate quantitative analysis of cefiderocol and ceftobiprole in human plasma using liquid chromatography-isotope dilution tandem mass spectrometry: interest for their therapeutic drug monitoring and pharmacokinetic studies. Clinical Chemistry and Laboratory Medicine, 2021, 59, 1800-1810.	2.3	11
9	Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19. Therapie, 2021, 76, 285-295.	1.0	8
10	Anti-Interleukin-6 and Janus Kinase Inhibitors for Severe Neurologic Toxicity of Checkpoint Inhibitors. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	18
11	Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers. Journal of the American College of Cardiology, 2020, 76, 292-302.	2.8	97
12	Electrocardiographic QT Intervals in Infants Exposed to Hydroxychloroquine Throughout Gestation. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008686.	4.8	16
13	Development and validation of a UPLC-MS/MS method for simultaneous quantification of levofloxacin, ciprofloxacin, moxifloxacin and rifampicin in human plasma: Application to the therapeutic drug monitoring in osteoarticular infections. Journal of Pharmaceutical and Biomedical Analysis, 2020, 183, 113137.	2.8	15
14	A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring <sc>SLE</sc>: Assessment by Drug Levels and Self-Administered Questionnaires. Clinical Pharmacology and Therapeutics, 2019, 106, 374-382.	4.7	30
15	Effect of topiramate on eating behaviours in Prader-Willi syndrome: TOPRADER double-blind randomised placebo-controlled study. Translational Psychiatry, 2019, 9, 274.	4.8	35
16	Sirolimus and mTOR Inhibitors: A Review of Side Effects and Specific Management in Solid Organ Transplantation. Drug Safety, 2019, 42, 813-825.	3.2	78
17	SAT0188â€¦WHOLE BLOOD VERSUS SERUM HYDROXYCHLOROQUINE LEVELS FOR DRUG MONITORING OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: PRELIMINARY RESULTS OF A PHARMACOLOGICAL STUDY. , 2019, , .		0
18	Development and Validation of a Fast Ultra-High Performance Liquid Chromatography-Fluorescent Method for the Quantification of Hydroxychloroquine and Its Metabolites in Patients With Lupus. Therapeutic Drug Monitoring, 2019, 41, 476-482.	2.0	14

#	ARTICLE	IF	CITATIONS
19	Influence of diluent volume of colistimethate sodium on aerosol characteristics and pharmacokinetics in ventilator-associated pneumonia caused by MDR bacteria. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1639-1646.	3.0	12
20	Prevention of Invasive Aspergillus Fungal Infections with the Suspension and Delayed-Release Tablet Formulations of Posaconazole in Patients with Haematologic Malignancies. <i>Scientific Reports</i> , 2018, 8, 1681.	3.3	14
21	Note of Republication: A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 1074-1082.	4.7	48
22	The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): An open-label prospective pilot study. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 693-699.e3.	1.2	59
23	Infliximab improves endothelial dysfunction in a mouse model of antiphospholipid syndrome: Role of reduced oxidative stress. <i>Vascular Pharmacology</i> , 2015, 71, 93-101.	2.1	21
24	The functional dlt operon of <i>Clostridium butyricum</i> controls the d-alanylation of cell wall components and influences cell septation and vancomycin-induced lysis. <i>Anaerobe</i> , 2015, 35, 105-114.	2.1	12
25	Dramatic response of a <i>BRAF</i> V600E-mutated primary CNS histiocytic sarcoma to vemurafenib. <i>Neurology</i> , 2014, 83, 1478-1480.	1.1	70
26	Simultaneous determination of rivaroxaban and dabigatran levels in human plasma by high-performance liquid chromatography-tandem mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 100, 230-235.	2.8	32
27	Dopa-decarboxylase gene polymorphisms affect the motor response to l-dopa in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 170-175.	2.2	50
28	Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil. <i>Arthritis and Rheumatism</i> , 2010, 62, 2047-2054.	6.7	85
29	Pharmacokinetic Study of Mycophenolate Mofetil in Patients with Systemic Lupus Erythematosus and Design of Bayesian Estimator Using Limited Sampling Strategies. <i>Clinical Pharmacokinetics</i> , 2008, 47, 277-284.	3.5	48